At CDMI Europe 2025, experts will discuss some of the newest technologies in data management and how these can be best ...

And good afternoon, and welcome everyone to the Relmada Therapeutics, Inc. Third Quarter 2025 Conference Call. 2025 is ...

Discover key insights from Trevi Therapeutics' Q3 2025 earnings call, including clinical progress, strong financials, and upcoming regulatory milestones.

As one provider moved from reactive paper-based management to proactive, tech-supported leadership, it has been focused on ...

Translational study shows that multiple immunological biomarkers predict the clinical activity of PDS0101 combination therapy PDS01ADC reprograms natural killer (NK) cells to possess characteristics ...

Get the latest on Curis, Inc.’s Q3 2025 earnings, clinical trial milestones, and investment outlook in rare lymphoma and CLL.

All-stock acquisition includes clinical-stage CD19/BCMA Dual-CAR T programAcquisition will expand existing advanced clinical-stage pipeline of amezalpat (PPAR- Antagonist, Phase 3-ready) and TPST-1495 ...

-- 63% complete response (CR) rate at any time (n=62); -- 56% CR rate at 3 months (n=62); -- 62% CR rate at 6 months (n=37), with 4 patients having successfully converted to CR post reinduction; and - ...

Agentic AI reshaping clinical workflows improves productivity, automates tasks, and enhances governance in health systems, says Dr. Tom Kelly of Heidi.

CORONA, CA – November 10, 2025 – PRESSADVANTAGE – Moment of Clarity has published a new resource, “TMS Therapy Success Rate ...

Although AI continues to expand across clinical and operational workflows, the median 2026 budget share for AI governance and ...